Results 61 to 70 of about 78,276 (237)

Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. [PDF]

, 2016
Capecitabine is commonly used in treating breast cancer; however, therapeutic response varies among patients and there is no clinically validated model to predict individual outcomes.
Abramson, Vandana, Forero, Andres, Huang, R Stephanie, LaCroix, Bonnie, Lenkala, Divya, Morrison, Gladys, Morrow, Phuong Khanh, Nanda, Rita, O'Donnell, Peter H, Rugo, Hope S, Van Poznak, Catherine, Ziliak, Dana   +11 more
core   +2 more sources

Characterizing Alzheimer’s Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record–Based Data

Clinical Pharmacology &Therapeutics, EarlyView.
Hypertension is a known modifiable risk factor for Alzheimer’s disease and related dementia (ADRD). However, it is unknown how variance in hypertension control, antihypertensive medications, and social determinants of health, such as social deprivation index (SDI), influence the risk of developing ADRD.
Eissa A. Jafari, Mona Alshahawey, Muhammad A. Zaman, Steven M. Smith, Yan Gong, Glenn E. Smith, Caitrin W. McDonough   +6 more
wiley   +1 more source

Expanding Pharmacist and Student Pharmacist Access to Genetics/Genomics/Pharmacogenomics Competency Education

Journal of Medical Education and Curricular Development, 2019
Background: As pharmacogenomics (PGx), a component of genetics/genomics and precision medicine, gains traction in the clinical setting, education of health care providers and health professions students must be made broadly available to improve ...
David F Kisor, Christopher L Farrell
doaj   +1 more source

Pharmacogenetics of analgesic drugs [PDF]

, 2013
• Individual variability in pain perception and differences in the efficacy of analgesic drugs are complex phenomena and are partly genetically predetermined.
Branford, R, Cregg, R, Gubbay, A, Russo, G, Sato, H   +4 more
core   +1 more source

An Update to the Clinical Pharmacogenetics Implementation Consortium (CPIC) SLCO1B1 Allele Functionality Table Leveraging Evidence from Participants of Predominantly Sub‐Saharan African Ancestry

Clinical Pharmacology &Therapeutics, EarlyView.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has formally updated the SLCO1B1 allele functionality table based on new evidence. Notably, the alleles studied (SLCO1B1 *9, *31, *41) are enriched in the genomes of patients historically excluded from pharmacogenomics research.
Akinyemi Oni‐Orisan, Sook Wah Yee, Tanushree Haldar, Michelle Whirl‐Carrillo, Kelly Caudle, Deepak Voora, Richard B. Kim   +6 more
wiley   +1 more source

Pharmacogenomics In Pharmacy Practice: Current Perspectives

Integrated Pharmacy Research and Practice, 2019
Hazem Elewa, Ahmed Awaisu College of Pharmacy, Qatar University Health, Qatar University, Doha, QatarCorrespondence: Hazem ElewaCollege of Pharmacy, Qatar University Health, Qatar University, P.O.
Elewa H, Awaisu A
doaj  

Navigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis

Clinical Pharmacology &Therapeutics, EarlyView.
Cisplatin is a chemotherapy drug that causes permanent hearing loss by damaging a critical tissue lining the inner ear, called the stria vascularis (SV). Currently, the molecular mechanisms of SV damage are largely unknown and the incidence of ototoxicity in patients cannot be reliably predicted.
Tara Lazetic, Deanne Nixie R. Miao, Britt I. Drögemöller, Alain Dabdoub, Julia M. Abitbol   +4 more
wiley   +1 more source

No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study

Pharmacogenomics and Personalized Medicine, 2021
Paul Y Takahashi,1 Euijung Ryu,2 Suzette J Bielinski,3 Matthew Hathcock,2 Gregory D Jenkins,2 James R Cerhan,3 Janet E Olson3 1Division of Community Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of ...
Takahashi PY, Ryu E, Bielinski SJ, Hathcock M, Jenkins GD, Cerhan JR, Olson JE   +6 more
doaj  

How Can We Move Clinical Genomics Beyond the Hype? [PDF]

, 2011
Examines the debate over increased use of genetic testing, due in part to lax regulation, and its consequences: wasteful spending, patient harm, and health system challenges.
Michael L. Millenson
core  

Context, ethics and pharmacogenetics [PDF]

, 2006
Most of the literature on pharmacogenetics assumes that the main problems in implementing the technology will be institutional ones (due to funding or regulation) and that although it involves genetic testing, the ethical issues involved in ...
Adam M. Hedgecoe, Akhtar, Anderson, Anon, Bazell, Beauchamp, Beeson, Brodaty, Brushwood, Clarke, DeVries, Emery, Ensom, Evans, Farlow, Farrer, Fox, Ginsburg, Haimes, Haseltine, Hedgecoe, Hedgecoe, Hoffmaster, Hoffmaster, Issa, Issa, Jazwinska, Johnson, Kumar, Kumar, Levine, Lindpaintner, Lindpaintner, McConnell, McLeod, Nelson, Noguchi, Nuffield Council on Bioethics., Palmer, Pfost, Poirier, Post, Relkin, Richard, Rioux, Ritchie, Robertson, Roses, Rothstein, Rusnak, Sadee, Saunders, Shi, Smith, Smith, Sugarman, Vaszar, Wolf, Zussman   +58 more
core   +1 more source